Skip to main content

Boehringer Ingelheim acquires Basel’s NBE-Therapeutics

| News

Boehringer Ingelheim to acquire Basel’s NBE-Therapeutics


German pharma group Boehringer Ingelheim is to acquire the Basel life sciences company NBE-Therapeutics for €1.18 billion. NBE-Therapeutics specializes in the development of cancer therapies.

NBE-Therapeutics is to become part of Boehringer Ingelheim. The Basel company is being acquired for €1.18 billion. It will remain at its campus at the Technology Park Basel and operate as a new site within Boehringer Ingelheim’s R&D network. ”This transaction is a validation of our platform and its potential for the next generation cancer therapies,” said Bertrand Damour, Chief Executive Officer of NBE-Therapeutics, in a press release.

The Basel biotech company is focused on antibody-drug conjugates (ADC) and advancing targeted cancer therapies derived from its immune stimulatory platform. The lead compound NBE-002 is currently in phase I clinical studies for triple negative breast cancer and other solid tumors.

Boehringer Ingelheim is gaining access to an innovative and unique platform that will decisively expand its cancer immunology portfolio. “We welcome NBE-Therapeutics’ richly talented team to Boehringer Ingelheim and we look forward to collaborating with them on this important work,” said Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors.

Boehringer Ingelheim expects to close the transaction in the first quarter of 2021.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.